CTLA4 and acute myeloid leukemia: Studies have shown that the combination of azacitidine, nivolumab and ipilimumab (an anti-CTLA-4 antibody) has achieved complete remission (CR) or complete remission with incomplete hematological recovery (CRi) in 3% of patients with AML (98).